- Home
- IMUX vs WEA Comparison
IMUX vs WEA Comparison
Compare IMUX & WEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IMUX | WEA |
|---|---|---|
| Founded | 2016 | 2002 |
| Country | United States | United States |
| Employees | 66 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.6M | 130.2M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | IMUX | WEA |
|---|---|---|
| Price | $1.18 | $10.96 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $4.80 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 23.3K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.87% |
| EPS Growth | ★ 38.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $10.30 |
| 52 Week High | $1.51 | $11.44 |
Technical Indicators
Market Signals| Indicator | IMUX | WEA |
|---|---|---|
| Relative Strength Index (RSI) | 53.23 | 61.06 |
| Support Level | $1.05 | $10.89 |
| Resistance Level | $1.35 | $11.33 |
| Average True Range (ATR) | 0.11 | 0.14 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 53.13 | 96.91 |
Price Performance
Historical ComparisonAbout IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
About WEA Western Asset Bond Fund Share of Beneficial Interest
Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The Fund invests in sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.